• Changes in body composition during and after adjuvant or neo-adjuvant chemotherapy in women with breast cancer stage I-IIIB compared with changes over a similar timeframe in women without cancer.

      van den Berg, M M G A; Kok, D E; Visser, M; de Vries, J H M; de Kruif, J Th C M; de Vries, Y; Posthuma, L; Sommeijer, D W; Timmer-Bonte, A; Los, M; et al. (2019-07-09)
    • Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts.

      Li, Kuanrong; Anderson, Garnet; Viallon, Vivian; Arveux, Patrick; Kvaskoff, Marina; Fournier, Agnès; Krogh, Vittorio; Tumino, Rosario; Sánchez, Maria-Jose; Ardanaz, Eva; et al. (2018-12-03)
      Few published breast cancer (BC) risk prediction models consider the heterogeneity of predictor variables between estrogen-receptor positive (ER+) and negative (ER-) tumors. Using data from two large cohorts, we examined whether modeling this heterogeneity could improve prediction. We built two models, for ER+ (Model Parity, number of full-term pregnancies, age at first full-term pregnancy and body height were only associated with ER+ tumors. Menopausal status, age at menarche and at menopause, hormone replacement therapy, postmenopausal body mass index, and alcohol intake were homogeneously associated with ER+ and ER- tumors. Internal validation yielded a C-statistic of 0.64 for Model Modeling heterogeneous epidemiological risk factors might yield little improvement in BC risk prediction. Nevertheless, a model specifically predictive of ER+ tumor risk could be more applicable than an omnibus model in risk assessment for chemoprevention.